JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB6992

Anti-CTGF 抗体

Anti-CTGF antibody

4

(29 Reviews)

|

(379 Publications)

Anti-CTGF antibody (ab6992) is a rabbit polyclonal antibody detecting CTGF in Western Blot, IP, IHC-P, IHC-Fr, ICC/IF. Suitable for Human, Mouse, Rat, Sheep.

- Over 310 publications
- Trusted since 2001

別名を表示する

CTGF, HCS24, IGFBP8, CCN2, CCN family member 2, Cellular communication network factor 2, Connective tissue growth factor, Hypertrophic chondrocyte-specific protein 24, Insulin-like growth factor-binding protein 8, IBP-8, IGF-binding protein 8, IGFBP-8

3 Images
Immunohistochemistry (Frozen sections) - Anti-CTGF antibody (AB6992)
  • IHC-Fr

CiteAb

Immunohistochemistry (Frozen sections) - Anti-CTGF antibody (AB6992)

CTGF Immunohistochemistry-immunofluorescence using Anti-CTGF antibody ab6992. Publication image and figure legend from Li, C., Zhen, G., et al., 2016, Nat Commun, PubMed 27126736.

Activation of RhoA promotes CTGF-VEGF complex formation in ECM, whereas inactivation of RhoA induces MMP3-mediated CTGF cleavage and VEGF release.(a-d) Immunofluorescence analysis of the binding of VEGF to ECM in different MSC cultures. MSCs were incubated with the indicated treatments for 7 days. Immunofluorescence staining was performed on non-permeabilized cells using antibodies against CTGF (a), fibronectin (b), collagen I (c) or VEGF (d). (e,f) MSCs were transfected with siRNA-control or siRNA-CTGF, then cultured with the indicated medium for 6 days. Western blot (WB) analysis of the cell lysates was performed using antibodies against CTGF and β-actin (e). Immunofluorescence staining was performed on non-permeabilized cells using antibodies against CTGF or VEGF (f). (g-j) WB and co-immunoprecipitation (IP) analyses of VEGF and CTGF in the overlay media of MSCs with different treatment. MSCs were incubated with the indicated treatments for 7 days. Overlay media : M1, M2, M3 and M4 were collected, respectively. Western blotting analysis of the overlay media was performed using antibodies against CTGF (g), MMP3 (h) and VEGF (i). Overlay media were subjected to IP assays using antibody against VEGF, the VEGF-associated CTGF was detected by western blotting with antibody against CTGF (j). (k,l) WB analysis of VEGF and CTGF in the ECMs of the cultured MSCs with different treatment. MSCs were incubated with the indicated treatment for 7 days. ECMs : E1, E2, E3 and E4 were collected. Western blotting analysis of the ECMs was performed using antibodies against CTGF (k) and VEGF (l). (m-o) WB and co-IP analysis of VEGF and CTGF in the overlay media of MSCs transfected with empty vector (EV) or L63RhoA. In the aliquots of the overlay medium collected from the cells overexpressed L63RhoA, 50 or 100 ng ml-1 rMMP3 was added and the reactions were maintained at 37 °C for 2 h. Overlay media were subjected to immunoprecipitation assays using antibody against VEGF, the VEGF-associated CTGF was detected by western blotting with antibody against CTGF (m). Western blotting analysis of the overlay media was performed using antibodies against CTGF (n) and MMP3 (o). Scale bars, 50 μm. Data are representative of three independent experiments.

Western blot - Anti-CTGF antibody (AB6992)
  • WB

CiteAb

Western blot - Anti-CTGF antibody (AB6992)

CTGF western blot using Anti-CTGF antibody ab6992. Publication image and figure legend from Choi, S. Y., Bae, H., et al., 2020, Nat Commun, PubMed 31980640.

FRC-specific depletion of Ltbr activates YAP/TAZ-induced myofibrosis.a Diagram for generation of indicated mice and their analyses at 8-weeks old. b Representative images and comparisons of indicated marker expressions on CCL19-YFP+ FRCs in WTΔFRC-YR and LtbrΔFRC-YR mice. Scale bars, 20 µm. c Representative images and comparisons of YAP and TAZ nuclear localization (white arrows) in inguinal LN of WTΔFRC and LtbrΔFRC mice. Scale bars, 20 µm. d Comparison of indicated mRNA expression in FRCs sorted from WTΔFRC and LtbrΔFRC mice. Each dot indicates a mean of quadruplicate values using n = 8-12 mice/group from three independent experiments. e Diagram for primary culture of FRCs derived from i-Lats1/2ΔFRC-TR mice and treatment with EtOH (control) or 4-OHT at 4 days after the culture and their analyses at 2 days after the treatment. f Immunoblot analysis of indicated proteins in primary cultured mouse FRCs after treatment with EtOH or 4-OHT for 2 days. g Comparisons of indicated mRNA expression normalized to Gapdh in primary cultured mouse FRCs after treatment with EtOH or 4-OHT for 2 days. Each dot indicates a mean of triplicate values from three independent experiments. h, i Representative images and comparisons of indicated marker expressions in primary cultured mouse FRCs after treatment with EtOH or 4-OHT for 2 days. Scale bars, 30 μm. Each dot indicates a mean of triplicate values from three independent experiments. j Diagram for primary culture of human FRCs for 4 days and infection with an adenovirus to induce overexpression of active YAP (YAP5SA) or TAZ (TAZ4SA) for their analyses at 2 days after the infection. k, l Representative images and comparisons of indicated marker expressions in primary cultured human FRCs infected with control-, YAP5SA-, or TAZ4SA-adenovirus. Scale bars, 30 μm. Each dot indicates a mean of triplicate values from three independent experiments. Unless otherwise denoted, each dot indicates a value obtained from one mouse and n = 5 mice/group pooled from two independent experiments. Horizontal bars indicate mean ± SD and P values versus WTΔFRC or WTΔFRC-YRby two-tailed Mann-Whitney U test except for (g), (i), and (l) (two-tailed Student's t-test). NS, not significant.

false

Western blot - Anti-CTGF antibody (AB6992)
  • WB

CiteAb

Western blot - Anti-CTGF antibody (AB6992)

CTFG western Blot using Anti-CTGF antibody ab6992. Publication image and figure legend from Cheong, M. L., Lai, T. H., et al. 2019, PLoS One PubMed 30695033.

Effects of TGFβ isoforms on collagen and CTGF protein and mRNA expression in HESCs.(A) Cells were treated with the indicated concentration of TGFβ1 for 16 h and then analyzed through Western blotting (n = 3). (B) Effect of TGFβ isoforms on collagen and CTGF mRNA expression in HESCs. Cells were treated with vehicle or TGFβ isoforms (ng/ml) for 4 h. The mRNA expression level of collagen, CTGF, and β-actin was analyzed through RT-PCR and densitometry (n = 2). *p < < 0.05, **p < < 0.01, and ***p < < 0.001 versus vehicle treatment only (basal).

false

Key facts

宿主種

Rabbit

クローン性

Polyclonal

アイソタイプ

IgG

キャリアフリー

No

交差種

Mouse, Rat, Sheep, Human

アプリケーション

IHC-Fr, IP, IHC-P, ICC/IF, WB, IHC-FoFr

applications

免疫原

Recombinant Fragment Protein within Mouse Ccn2 aa 200 to C-terminus. The exact immunogen used to generate this antibody is proprietary information.

P29268

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "IP" : {"fullname" : "Immunoprecipitation", "shortname":"IP"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"}, "IHCFoFr" : {"fullname" : "Immunohistochemistry (PFA perfusion fixed frozen sections)", "shortname":"IHC-FoFr"}, "IHCP" : {"fullname" : "Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)", "shortname":"IHC-P"}, "ICCIF" : {"fullname" : "Immunocytochemistry/ Immunofluorescence", "shortname":"ICC/IF"}, "IHCFr" : {"fullname" : "Immunohistochemistry (Frozen sections)", "shortname":"IHC-Fr"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "IP-species-checked": "guaranteed", "IP-species-dilution-info": "", "IP-species-notes": "<p></p>", "WB-species-checked": "guaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p>Block membrane in 4% BSA in Tris-buffered saline containing 0.05% Tween 20 (TBST). See Fu M et al.</p>", "IHCFoFr-species-checked": "guaranteed", "IHCFoFr-species-dilution-info": "", "IHCFoFr-species-notes": "<p></p>", "IHCP-species-checked": "guaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>", "ICCIF-species-checked": "guaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>", "IHCFr-species-checked": "guaranteed", "IHCFr-species-dilution-info": "", "IHCFr-species-notes": "<p>See Ueberham et al.</p>" }, "Mouse": { "IP-species-checked": "guaranteed", "IP-species-dilution-info": "", "IP-species-notes": "<p></p>", "WB-species-checked": "guaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p>Block membrane in 4% BSA in Tris-buffered saline containing 0.05% Tween 20 (TBST). See Fu M et al.</p>", "IHCFoFr-species-checked": "guaranteed", "IHCFoFr-species-dilution-info": "", "IHCFoFr-species-notes": "<p></p>", "IHCP-species-checked": "guaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>", "ICCIF-species-checked": "guaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>", "IHCFr-species-checked": "guaranteed", "IHCFr-species-dilution-info": "", "IHCFr-species-notes": "<p>See Ueberham et al.</p>" }, "Rat": { "IP-species-checked": "guaranteed", "IP-species-dilution-info": "", "IP-species-notes": "<p></p>", "WB-species-checked": "guaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p>Block membrane in 4% BSA in Tris-buffered saline containing 0.05% Tween 20 (TBST). See Fu M et al.</p>", "IHCFoFr-species-checked": "guaranteed", "IHCFoFr-species-dilution-info": "", "IHCFoFr-species-notes": "<p></p>", "IHCP-species-checked": "guaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>", "ICCIF-species-checked": "guaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>", "IHCFr-species-checked": "guaranteed", "IHCFr-species-dilution-info": "", "IHCFr-species-notes": "<p>See Ueberham et al.</p>" }, "Cow": { "IP-species-checked": "predicted", "IP-species-dilution-info": "", "IP-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "", "IHCFoFr-species-checked": "predicted", "IHCFoFr-species-dilution-info": "", "IHCFoFr-species-notes": "", "IHCP-species-checked": "predicted", "IHCP-species-dilution-info": "", "IHCP-species-notes": "", "ICCIF-species-checked": "predicted", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "", "IHCFr-species-checked": "predicted", "IHCFr-species-dilution-info": "", "IHCFr-species-notes": "" }, "Sheep": { "IP-species-checked": "guaranteed", "IP-species-dilution-info": "", "IP-species-notes": "<p></p>", "WB-species-checked": "guaranteed", "WB-species-dilution-info": "", "WB-species-notes": "<p>Block membrane in 4% BSA in Tris-buffered saline containing 0.05% Tween 20 (TBST). See Fu M et al.</p>", "IHCFoFr-species-checked": "guaranteed", "IHCFoFr-species-dilution-info": "", "IHCFoFr-species-notes": "<p></p>", "IHCP-species-checked": "guaranteed", "IHCP-species-dilution-info": "", "IHCP-species-notes": "<p></p>", "ICCIF-species-checked": "guaranteed", "ICCIF-species-dilution-info": "", "ICCIF-species-notes": "<p></p>", "IHCFr-species-checked": "guaranteed", "IHCFr-species-dilution-info": "", "IHCFr-species-notes": "<p>See Ueberham et al.</p>" } } }

製品の詳細

Product Specifications

Anti-CTGF antibody (ab6992) is a rabbit polyclonal antibody and is validated for use in ICC/IF, IHC-FoFr, IHC-Fr, IHC-P, IP, WB in human, mouse, rat, sheep samples.
Anti-CTGF antibody (ab6992) specifically detects CTGF (UniProt ID: P29268; Molecular weight: 35kDa) and is sold in 50 µg selling sizes.

Quality and Validation

Abcam's high quality validation processes ensure Anti-CTGF antibody (ab6992) has high sensitivity and specificity.
Anti-CTGF antibody (ab6992) has been cited over 313 times in peer reviewed journals and is trusted by the scientific community.
Anti-CTGF antibody (ab6992) has 28 independent reviews from customers.

Target Information

Connective Tissue Growth Factor (CTGF), also known as CCN2 is a protein that regulates various biological process including cell proliferation and migration. CTGF influences the tumor microenvironment by promoting angiogenesis, inflammation, and activation of cancer-associated fibroblasts (CAFs). Elevated levels of CTGF have been observed in several cancers, such as pancreatic, breast, and liver cancers.

出荷温度及び保存条件

製品の状態
Liquid
精製方法
Affinity purification Protein A
バッファー組成
pH: 6.5 Preservative: 0.1% Sodium azide Constituents: PBS
出荷温度
Blue Ice
短期保存期間
1-2 weeks
短期保存温度
+4°C
長期保存温度
-20°C
分注に関する情報
Upon delivery aliquot
保管に関する情報
Avoid freeze / thaw cycle

補足情報

This supplementary information is collated from multiple sources and compiled automatically.

CTGF also known as Connective Tissue Growth Factor is a significant protein in the CCN family involved in regulating various cellular functions. CTGF has a molecular weight of approximately 36-38 kDa. It is highly expressed in tissues such as the skin kidney and vascular tissues. This protein is secreted and can be found in the extracellular matrix where it interacts with other cellular components to mediate its effects.
Biological function summary

Connective Tissue Growth Factor plays an important role in cell adhesion proliferation and differentiation. It operates as an independent protein but can also be part of the extracellular matrix structure. CTGF functions as a mediator in the interaction between cells and their surrounding environment influencing processes such as angiogenesis and wound healing through these interactions.

Pathways

CTGF fits into the TGF-beta and Wnt signaling pathways where it helps modulate cellular responses to external stimuli. It interacts with proteins like fibronectin and integrins within these pathways enhancing cellular communication and response. These pathways are fundamental for both development and pathological conditions showing CTGF's influence on various biological processes.

CTGF shows a strong connection with fibrosis and cancer. In fibrotic conditions the CTGF protein interacts with collagen and fibronectin leading to excessive deposition in tissues. In cancers CTGF may promote tumor progression by facilitating angiogenesis and promoting invasive behaviors in tumors. These interactions highlight CTGF's role as a target for therapeutic strategies aimed at treating these diseases.

製品プロトコール

For this product, it's our understanding that no specific protocols are required. You can visit:

ターゲットの情報

Major connective tissue mitoattractant secreted by vascular endothelial cells. Promotes proliferation and differentiation of chondrocytes. Is involved in the stimulation of osteoblast differentiation and has a critical role in osteogenesis (PubMed : 39414788). Mediates heparin- and divalent cation-dependent cell adhesion in many cell types including fibroblasts, myofibroblasts, endothelial and epithelial cells. Enhances fibroblast growth factor-induced DNA synthesis.
See full target information CCN2

文献 (379)

Recent publications for all applications. Explore the full list and refine your search

Physiological reports 13:e70546 PubMed40969144

2025

Left ventricular pressure-loading improves pressure-induced right ventricular remodeling by redistributing mechanical load and reducing mechanosignaling.

Applications

Unspecified application

Species

Unspecified reactive species

Xavier Alexander Lee,Sonja Raschzok,Jean-Francois Desjardins,Tim Van Loon,Andrija Plavetic,Omar Kanny,Golam Kabir,Linda Nghiem,John Dauz,Andras Kapus,Joost Lumens,Kim A Connelly,Mark K Friedberg

iScience 28:112608 PubMed40502710

2025

The single-cell transcription reveals the aberrant differentiation trajectory of chondrocytes in the intervertebral disc for congenital scoliosis.

Applications

Unspecified application

Species

Unspecified reactive species

Junfeng Wang,Haodong Li,Dong Fu,Yiming Zheng,Chuang Qian,Lin Li,Maoxiang Qian,Dahui Wang

Materials today. Bio 32:101757 PubMed40290884

2025

ROS-responsive drug delivery system with enhanced anti-angiogenic and anti-inflammatory properties for neovascular age-related macular degeneration therapy.

Applications

Unspecified application

Species

Unspecified reactive species

Jiayi Zuo,Yining Pan,Yuanli Wang,Wei Wang,Haojie Zhang,Si Zhang,Youru Wu,Jiangfan Chen,Qingqing Yao

International journal of molecular sciences 26: PubMed40243677

2025

Apixaban Inhibits Progression of Experimental Diabetic Nephropathy by Blocking Advanced Glycation End Product-Receptor Axis.

Applications

Unspecified application

Species

Unspecified reactive species

Takanori Matsui,Ami Sotokawauchi,Yuri Nishino,Yoshinori Koga,Sho-Ichi Yamagishi

JCI insight 10: PubMed40232859

2025

Characterization of a pathogenic nonmigratory fibroblast population in systemic sclerosis skin.

Applications

Unspecified application

Species

Unspecified reactive species

Kristina En Clark,Shiwen Xu,Moustafa Attar,Voon H Ong,Christopher D Buckley,Christopher P Denton

African health sciences 24:276-285 PubMed40190527

2025

The interaction between CTGF and VEGF-A in the progression of intervertebral disc fibrosis.

Applications

Unspecified application

Species

Unspecified reactive species

Wangbing Xu,Jiqin Zhong,Jianrong Jian,Faming Zhong

Nature communications 16:3251 PubMed40185752

2025

Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment.

Applications

Unspecified application

Species

Unspecified reactive species

Vanessa Neiens,Eva-Maria Hansbauer,Thomas J Jaquin,Janet K Peper-Gabriel,Poornima Mahavadi,Mark E Snyder,Maximilian J Grill,Cornelia Wurzenberger,Antonio Konitsiotis,Adriana Estrada-Bernal,Kristina Heinig,Athanasios Fysikopoulos,Nicolas Schwenck,Stefan Grüner,Denis Bartoschek,Theresia Mosebach,Sandra Kerstan,Joe Wrennall,Marleen Richter,Kentaro Noda,Konrad Hoetzenecker,Janette K Burgess,Robert Tarran,Claudia Wurzenberger,Karl-Robert Wichmann,Jonas Biehler,Kei W Müller,Andreas Guenther,Oliver Eickelberg,Mary F Fitzgerald,Shane A Olwill,Gabriele Matschiner,Marina Pavlidou

British journal of pharmacology 182:2560-2581 PubMed39965654

2025

Imatinib aggravates pressure-overload-induced right ventricle failure via JNK/Runx2 pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Xiaohui Zeng,Zhuoji Ma,Shanshan Wen,Liang Zhou,Wanxian Hong,Zhixiong Wu,Chunxian Cen,Qianwen Bai,Shangwei Ding,Xin Chen,Jian Wang,Lingdan Chen,Wenju Lu,Tao Wang

Clinical and translational medicine 15:e70189 PubMed39956959

2025

5-hydroxymethylcytosine features of portal venous blood predict metachronous liver metastases of colorectal cancer and reveal phosphodiesterase 4 as a therapeutic target.

Applications

Unspecified application

Species

Unspecified reactive species

Nuo Xu,Zhaoya Gao,Deyan Wu,Hangyu Chen,Zijian Zhang,Lei Zhang,Yuchen Wang,Xuyang Lu,Xu Yao,Xuelan Liu,Yi-You Huang,Meiying Qiu,Sen Wang,Jinqiang Liang,Can Mao,Feng Zhang,Huimin Xu,Yujiao Wang,Xian Li,Zhexin Chen,Dandan Huang,Jingyi Shi,Wensheng Huang,Fuming Lei,Zeruo Yang,Long Chen,Chuan He,Haichuan Zhu,Hai-Bin Luo,Jin Gu,Jian Lin

Respiratory research 26:51 PubMed39939959

2025

YAP as a potential therapeutic target for myofibroblast formation in asthma.

Applications

Unspecified application

Species

Unspecified reactive species

Yanrong Guo,Yuran Zhou,Rui Wang,Yujing Lin,Huimin Lan,Yang Li,De-Yun Wang,Jinrui Dong,Kefeng Li,Yan Yan,Yongkang Qiao
View all publications

Abcam product promise

当社は、高品質な試薬を通じてお客様の研究を力強くサポートすることをお約束いたします。ご使用いただく各段階で、常にお客様をサポートできる体制を整えております。万が一、製品が期待通りに機能しない場合は、「Abcam Product Promise」による当社保証制度に基づき、安心してご利用いただけます。
保証に関する詳細については利用規約をご確認ください。

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com